Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG:2335)

HKG:2335 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Operating Income Operating Income Growth	-265.24	-153.58	-125.83
Net Income Net Income Growth	-364.44	-182.51	-154.63
Earnings Per Share EPS Growth	-1.42	-0.75	-0.66
EPS Growth	-	-	-

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Cash & Investments Cash & Investments Growth	1,193	236.07	179.81
Total Debt Total Debt Growth	1.65	1,209	74.89
Net Cash (Debt) Net Cash Growth	1,192	-972.65	104.93
Net Cash Growth	-	-	-
Net Cash Per Share Net Cash Per Share Growth	4.64	-4.00	0.45

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Operating Cash Flow Operating Cash Flow Growth	24.34	-137.13	-107.74
Capital Expenditures CapEx Growth	-1.29	-0.88	-1.3
Free Cash Flow Free Cash Flow Growth	23.05	-138.01	-109.04
Free Cash Flow Growth	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Aug 28, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 10, 2026

Data Sources Report a data error